AP
SUPN icon

Aspect Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Aspect Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42K Hold
52
– – ﹤0.01% 500
2026
Q1 		$2.69K Hold
52
– – ﹤0.01% 445
2025
Q4 		$2.58K Hold
52
– – ﹤0.01% 481
2025
Q3 		$2.48K Buy
+52
New +$2.09K ﹤0.01% 508

Other funds holding SUPN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
CNAM
Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
JIR
James Investment Research Alpha, Ohio $984M AUM 36.03% 1-Year Est. Return

Aspect Partners's SUPN Position: Q2 2026 in Review

Aspect Partners held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 52 shares worth $2.42K. The position accounts for ﹤0.01% of the portfolio, ranked #500.

Aspect Partners first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.69K in Q1 2026. 58 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Aspect Partners held 52 shares of Supernus Pharmaceuticals worth $2.42K as of Q2 2026.
  • Aspect Partners left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #500 holding.
  • Aspect Partners first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Aspect Partners's Supernus Pharmaceuticals position peaked at $2.69K in Q1 2026.
  • 58 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.